title: What are the most important barriers for thrombolytic therapy in ischemic stroke patients?
authors.forename: Hormoz
authors.initials: H
authors.lastname: Ayromlou
authors.forename: Hassan
authors.initials: H
authors.lastname: Soleimanpour
authors.forename: Mehdi
authors.initials: M
authors.lastname: Farhoudi
authors.forename: Elyar
authors.initials: E
authors.lastname: Sadeghi-Hokmabadi
authors.forename: Rouzbeh
authors.initials: R
authors.lastname: Rajaei Ghafouri
authors.forename: Ehsan
authors.initials: E
authors.lastname: Sharifipour
authors.forename: Somayeh
authors.initials: S
authors.lastname: Mostafaei
authors.forename: Mehdi
authors.initials: M
authors.lastname: Najafi Nashali
mesh_terms: D000368:Aged; D002545:Brain Ischemia / Q000175:diagnosis* / Q000188:drug therapy*; D042241:Early Diagnosis; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D007492:Iran; D008297:Male; D010960:Plasminogen Activators / Q000627:therapeutic use; D020521:Stroke / Q000175:diagnosis* / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D014057:Tomography, X-Ray Computed / Q000592:standards; D014187:Transportation of Patients
chemical_list: D010960:Plasminogen Activators